Ovid Therapeutics Inc. (OVID)

2.0600 0.0000 (0.00%) At close: 04:00PM EDT

Ovid Therapeutics Inc.

1460 Broadway
Suite 15021
New York, NY 10036
United States
646 661 7661
https://www.ovidrx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 57

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	Pres, CEO & Chairman	861.24k	N/A	1953
Mr. Jeffrey A. Rona	Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer	494.5k	N/A	1968
Mr. Thomas Michael Perone J.D., M.B.A.	Gen. Counsel, Chief Compliance Officer & Corp. Sec.	633.37k	N/A	1965
Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP	Founder & Member of Scientific Advisory Board	N/A	N/A	1957
Mr. Jason Tardio M.B.A.	Chief Commercial Officer & COO	N/A	N/A	1978
Ms. Lora Pike	Sr. Director of Investor Relations & PR	N/A	N/A	N/A
Ms. Suzanne K. Wakamoto SHRM-SCP, SPHR	Sr. VP of HR	N/A	N/A	N/A
Dr. Dirk Haasner	Sr. VP of Global Manufacturing & CMC QA	N/A	N/A	1965
Dr. Claude Nicaise M.D.	Head of R&D	N/A	N/A	1953
Mr. Luke Rosen	Sr. VP of Accelerated Devel. & Community Engagement	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

Ovid Therapeutics Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.